Skip to site menu Skip to page content
Logo Image
In Brief
Spotlight

Eli Lilly outlays $2.3bn to acquire blood cancer specialist Ajax Therapeutics

Ajax’s lead asset is AJ1-11095, a once-daily Type II JAK2 inhibitor taken orally, which is currently in a Phase I trial.

Latest news

Seaport and Hemab target $180m IPOs as biotech listings accumulate

Seaport will use the funds for its neuropsychiatric drug pipeline, while Hemab will focus on bleeding disorder medicines.

Merck KGaA and Remepy join forces to develop combo drug-digital therapies

The pair will develop drug-digital therapeutic combinations as a singular product, thus sidestepping reimbursement hurdles linked to individually approved digital therapies.

FDA approves AstraZeneca’s Saphnelo for SLE

The approval is supported by results from the Phase III TULIP-SC trial.

MFN changing the rules of the game for the Nordic countries

Recent GlobalData POLI analysis showed a 35% decline in pharmaceutical launches across Europe in the ten months after the introduction of IRP in the US.

ESCMID Global 2026: Pritelivir excels in immunocompromised refractory HSV patients

Aicuris’s pritelivir is forecast to be a significant advancement for immunocompromised patients with refractory HSV infections.

Pharma Meets AI Conference 2026: AI governance shifts to embedded practice

AI capabilities within pharma are evolving from add-on to an arm of core business demanding overhauled AI governance.

Early detection of bowel Cancer in the UK represents success of screening program

With the introduction of a home testing kit, it is easier for people to get screened for bowel cancer.